Dapsone, with or without trimethoprim or pyrimethamine, has strong anti-Pneumocystis carinii activity, as demonstrated by in vitro methods, animal studies, and clinical trials. The drug blocks folic acid synthesis of P. carinii by inhibition of dihydropteroate synthetase activity. Dapsone is efficiently absorbed (70% -80%) from the gastrointestinal tract, reaches peak serum concentration in 2 -6 hours, and is adequately distributed to the fluid of the alveolar spaces. Synergistic effects against P. carinii are noted when trimethoprim is combined with dapsone. This combination is recommended for therapeutic use for P. carinii pneumonia (PCP) as an alternative for patients who cannot take trimethoprim-sulfamethoxazole (TMP-SMZ). Evidence from more than 40 studies of dapsone as prophylaxis for PCP in AIDS patients shows that dapsone, either alone or in combination with pyrimethamine, is as effective as aerosolized pentamidine or atovaquone but slightly less effective than TMP-SMZ. Adverse effects include rash, anemia, methemoglobinemia, agranulocytosis, and hepatic dysfunction. Desensitization can be accomplished with many cases. Dapsone is the most cost-effective prophylaxis currently available for PCP.
Since 1984, when dapsone was first found to have activity of mycobacteria, including Mycobacterium avium complex. In combination with pyrimethamine, dapsone has been used sucagainst Pneumocystis carinii [1] , ú200 publications have addressed the use of this drug in the prevention and treatment of cessfully as chemoprophylaxis for malaria due to chloroquineresistant Plasmodium falciparum and Plasmodium vivax.
P. carinii pneumonia (PCP). Reports have been limited almost exclusively to clinical studies of patients with HIV infection
With or without trimethoprim (TMP) or pyrimethamine, dapsone has been shown in animal and human studies to effectively and to experimental studies of the corticosteroid-treated rat model. These investigations have been adequate to give a reaprevent and treat PCP. Some evidence suggests it has activity against Toxoplasma gondii. sonable perspective on the use of dapsone in the management of PCP, especially for prophylaxis. The purpose of this article is to review all publications, as well as studies presented at Mechanisms of Action national and international meetings, and to provide pertinent information on the use of this drug for PCP in the immunocomDapsone was first synthesized from para-chloronitrobenzene promised host.
in 1945 [2] and first marketed in the United States in 1957. The drug is an analog of para-Aminobenzoic acid and acts Antimicrobial Activities of Dapsone through the inhibition of folic acid synthesis in susceptible organisms. It is an inhibitor of the dihydropteroate synthetase Dapsone-USP, 4-4-diaminodiphenylsulfone, is a synthetic sulof P. carinii. Voeller et al. [3] found that a 1.5-mM concentrafone with bactericidal and bacteriostatic activity against Mycotion of dapsone inhibited 50% of P. carinii dihydropteroate bacterium leprae and is effective in the treatment of patients with synthetase activity. In another study, 0.4 mM of dapsone was leprosy. It is also active in high concentrations ( §10 mg/mL) effective when tested in an in vitro culture [4] . against Mycobacterium tuberculosis and several other species Dapsone may conceivably affect P. carinii infection by mechanisms other than intervention with folic acid synthesis. In vitro studies have shown that dapsone stimulates neutrophil patients with and without PCP [6] compared the ability of their Dapsone is available in 25-mg and 100-mg tablets. No intravenous formulation has been developed for commercial use. neutrophils to activate the respiratory burst. When stimulated with P. carinii, neutrophils from the patients with a history of In healthy adults dapsone is slowly but efficiently absorbed from the gastrointestinal tract, with 70% -80% bioavailability PCP had a significantly lower response than those from the other groups studied.
in an acidic environment. Peak serum concentrations of 1.7 mg/mL to 1.9 mg/mL are achieved in 2 -6 hours after a dose The in vitro experiments of Bozeman et al. [7] suggest that dapsone could prevent myeloperoxidase-and eosinophil peroxof 100 mg. The drug is well distributed throughout total-body water and all tissues. The plasma half-life may vary from 10 idase -mediated tissue injury at sites where the peroxidase enzymes are secreted and diluted into the neutral pH environment to 50 hours, with a mean time of 30 hours, for both dapsone and MADDS. About 70% -85% of the drug is excreted in the of the tissue interstitial space. However, dapsone did not inhibit peroxidase-mediated antimicrobial activity, occurring at high urine. Enterohepatic circulation following biliary excretion of free drug also occurs, accounting for prolonged persistence in enzyme concentrations in the acid environment of the phagolysosomes. Whether or not dapsone affects neutrophil motility the plasma after drug administration is stopped [10] . In children with HIV infection, pharmacokinetic studies and function to the extent that a discernible therapeutic impact occurs is not known.
show that clearance (CL) and V ss (apparent volume of distribution of steady state) of dapsone are approximately twofold Some in vitro studies suggest dapsone might have some effect on HIV replication [8] . In phytohemagglutinin P-activated HIVgreater than in adults, while the t 1 2 is comparable [11] . The 1-infected peripheral blood mononuclear cells, dapsone (2-10 dose of 2.0 mg/kg (not to exceed a total dose of 100 mg/d) ng/mL) decreased cell proliferation and HIV-1 replication. Howadministered at the same frequency used in adults may be used ever, dapsone increased HIV-1 replication in peripheral blood for prophylaxis for and treatment of PCP. lymphocytes and monocyte-derived macrophages. Dapsone meDapsone is readily soluble at normal acidic gastric pH and tabolites are potent oxidants that induce glutathione consumption remains insoluble at neutral pH. Because some drugs given to counteract oxidative processes. It can be speculated that periphconcomitantly with dapsone are absorbed best at alkaline pH, eral blood lymphocytes and monocyte-derived macrophages may such as didanosine, concern has been expressed about the effect be able to generate N-hydroxyl-dapsone metabolically upon exof alkalinization on the efficacy of dapsone [12] . In a prospecposure to dapsone. This may, in turn, induce a glutathione deficit tive study in which volunteers were given 100 mg of dapsone in these cells and an oxidative exhaustion that leads to IL-2-plus Maalox C (Novartis Consumer Health, Summit, NJ), the dependent proliferation of lymphocytes or enhancement of HIV antacid was found to facilitate rather than impair absorption of replication, or both. Duval et al. [8] found these activating effects dapsone [13] . At present there are no sound data to suggest at concentrations from 1 ng/mL to 10 ng/mL. Dapsone serum that clinicians need to modify the gastric acidity of patients concentrations in HIV-infected patients given the drug range from during the use of dapsone. 1.5 ng/mL to 4.2 ng/mL [9] .
HIV-infected patients rarely receive dapsone without conAs with many drugs, the activity of dapsone may not be comitant medications. The pharmacokinetic interactions of zilimited to its effect on a single target in cell replication. Its dovudine, TMP, and dapsone in HIV-infected patients have effect on the dihyhdropteroate synthetase of P. carinii is estabbeen studied [14] . Zidovudine did not influence the pharmacolished. It seems reasonable to expect the anti-inflammatory kinetic profile of dapsone, and dapsone had no effect on the activity demonstrated in cases of leprosy, dermatitis herpetipharmacokinetic disposition of zidovudine. However, TMP deformis, and other conditions would also occur in cases of PCP.
creased the renal clearance of zidovudine by 58%. There was also a concurrent 54% decrease in urinary recovery of zidovudine. The mean area under the concentration curve from zero Metabolism and Pharmacokinetics to 6 hours of the zidovudine-glucuronide/zidovudine ratio was At least two major metabolites come from biotransformation unchanged. The data indicate that zidovudine, TMP, and dapof dapsone: monoacetyl dapsone (MADDS) and dapsone hysone can be given concomitantly to AIDS patients without droxylamine. Neither contributes to the therapeutic affect of clinically significant interactions. However, with impaired liver function and impaired glucuronidation, the doses of zidovudine the drug. Dapsone is acetylated to MADDS by N-acetyltransmay need to be decreased. ferase in the liver. MADDS may also be acetylated to dapsone, In Malaysian leprosy patients, rifampin was found to deand an equilibrium may be reached within a few hours after administration. There are no significant differences between crease the plasma t 1 2 of dapsone by 22% -83%, probably by slow and fast acetylators in the frequency and type of side enhancing hepatic clearance by induction of microsomal eneffects, plasma concentrations, and therapeutic efficacy in nonzymes [15] . Because plasma concentrations of dapsone are PCP conditions. The second major metabolite is N-hydroxyl-0.1 -7.0 mg/mL with a dose of 200 mg and the MIC (in cell ated to dapsone hydroxylamine in the liver by the mixed oxiculture) is 0.1 -10 mg/mL, the concomitant use of rifampin and dase system in the presence of oxygen and NADPH. This dapsone could compromise the efficacy of the latter drug [16] . Population pharmacokinetics of dapsone were examined in metabolite has been associated with hematologic toxicity. HIV-infected patients receiving 100 mg of dapsone twice for once-a-week dosing of dapsone for PCP prophylaxis. Unfortunately, no studies of dapsone combined with TMP in weekly. Rifampin was found to increase the values of clearance/bioavailability (CL/F) and volume of clearance/bioavailweekly doses have been performed. ability (V/F) by Ç70% (CL/F and V/F were 1.83 L/h and 69.6 L, respectively, in those not taking rifampin) [17] .
Experimental Studies in Animals In AIDS patients successfully treated for PCP, the mean peak dapsone level of 2.1 mg/mL was achieved 6 hours after Because of the remarkably high incidence of naturally acquired P. carinii infection in rats, the administration of corticoadministration of TMP/dapsone [18] . Dapsone and TMP plasma concentrations were both higher when the drugs were steroid immunosuppression for 4 -6 weeks or longer results in the provocation of extensive P. carinii pneumonitis from the given concomitantly than when given separately. Plasma concentrations of dapsone were 40% higher in patients treated latent infection in 70% -100% of animals. This experimental animal model has been used to screen and identify drugs for with TMP/dapsone than in those treated with the same dose of dapsone alone (2.1 mg/mL vs. 1.5 mg/mL). The concentration anti -P. carinii activity [21, 22] . Almost without exception, drugs found effective in rat studies have been effective in of TMP was 45% higher in patients treated with TMP/dapsone than in those treated with TMP-sulfamethoxazole (SMZ) (18.8 humans with PCP. In 1984, Hughes and Smith [1] screened several drugs and mg/mL vs. 12.4 mg/mL).
In a subsequent study the same authors were not able to found that a 25-mg/(kgrd) dosage of dapsone was totally effective in preventing P. carinii infection. Dapsone was then evaludemonstrate increased concentrations when these drugs were given concomitantly [14] . However, the former study evaluated ated at dosages of 5, 25, and 125 mg/(kgrd) and compared with TMP-SMZ given at 50/250 mg/(kgrd) orally. The two a larger group of patients receiving treatment for PCP, while the latter study involved only six asymptomatic patients. Until highest dosages of dapsone and TMP-SMZ prevented the infection in 100% of animals, and the lowest dosage of dapsone more definitive data are available, the extent of drug interaction is unclear. One can conclude at least that no antagonistic effects (5.0 mg/[kgrd]) prevented it in 40% of all rats. All of the untreated control animals developed PCP. Therapeutic efficacy are at play.
Because infection with P. carinii and the disease it causes was determined by allowing animals to develop extensive PCP and then initiating drug therapy. Based on the extent of residual are located almost exclusively in the lung, it is critical that drug activity and concentration be maximal in the lung parenpneumonitis at the completion of treatment, the frequency of PCP was reduced to 50% by TMP-SMZ and to 25% by dapchyma and alveolar space. Cruciani et al. [19] studied the penetration of dapsone into epithelial lining fluid of HIV-infected sone, while all of the untreated controls had extensive PCP. In later studies [23] the efficacies of TMP-SMZ, TMP/dappatients receiving prophylaxis with dapsone (100 mg twice weekly). The bronchoalveolar lavage (BAL) fluid and plasma sone, dapsone, and pentamidine were compared for the prevention of PCP in the corticosteroid-treated rat model. While 11 samples were studied for dapsone concentrations. The mean concentrations in BAL fluid at 2, 4, 12, 24, and 48 hours after (73%) of 15 untreated control animals had PCP after 10 weeks of immunosuppression, none of the animals given 125 mg of the dose of 100 mg were 0.9, 0.7, 1.55, 0.23, and 0.45 mg/L, respectively. These concentrations were 76%, 79%, 115%, dapsone per kg daily, weekly, biweekly, or monthly had evidence of infection. Of the 10 rats given a single dose of dapsone 65%, and 291% respectively, of those observed in plasma at the same times. This study suggests that dapsone is well distrib-23 and 50 days after immunosuppression was started, five (50%) developed P. carinii pneumonia. When three drugs were uted into the epithelial lining fluid and that administration of 100 mg of dapsone twice a week provides sustained concentragiven separately to groups of 10 rats in single doses every other week, PCP occurred in 40% of those treated with TMPtions in the tissue compartment.
The pharmacokinetics and safety of weekly dapsone and SMZ, in none of those treated with TMP/dapsone, and in all of those given pentamidine. dapsone plus pyrimethamine in adults with AIDS were studied [20] . Of three doses -100 mg, 200 mg, and 300 mg of dapsone
The experiments showed that dapsone is highly effective in chemoprophylaxis for PCP when given at monthly intervals or weekly -200 mg weekly was established as the maximum tolerated dose. This dose was then found to be well tolerated more frequently and that dapsone and TMP/dapsone are more effective than TMP-SMZ when given at biweekly intervals. It in combination with pyrimethamine (25 mg).
In another study [9] , median plasma concentrations of dapseems reasonable to expect that at least weekly or even biweekly doses of dapsone or TMP/dapsone would provide an sone and pyrimethamine during day 1 after ingestion of 200 mg of dapsone and 75 mg of pyrimethamine were 1.04 effective and reasonably safe chemoprophylaxis regimen for patients at high risk for PCP. mg of dapsone and 0.36 mg of pyrimethamine per mL. By day 6 -7 the dapsone concentration decreased to õ20 ng/mL, but Separate studies of dapsone in the rat model [24, 25] and in a mouse model of severe combined immunodeficiency [26] the pyrimethamine level remained elevated at 0.13 mg/mL. Concurrent administration of didanosine did not decrease the have also shown dapsone to have potent anti -P. carinii activity. Walzer et al.
[27] found dapsone alone to be effective in drug concentrations. These data tend to support the potential / 9c51$$jy36 06-16-98 00:27:17 cida UC: CID Hughes CID 1998; 27 (July) murine PCP and that Ro 11-8958, an analog of TMP, enhanced Although the numbers of patients studied were small, the 100% successful response rate with dapsone/TMP suggested the efficacy of dapsone. In an animal model with dual infections of PCP and toxoplasmosis, Brun-Pascaud et al. [28] found the the combination was more efficacious than dapsone alone (61% successful response rate). Furthermore, it is noteworthy that drug combination of pyrimethamine (3 mg/kg) plus dapsone (25 mg/kg or 50 mg/kg) administered daily totally prevented major toxicity was noted in none of the patients treated with dapsone alone, in 13% of those treated with dapsone/TMP, and both infections. In another study, a diformyl derivative of dapsone, 4-4-sulfonylbisformanilide, was found to have efficacy in 51% of recipients in the comparable study with TMP-SMZ. Whether or not TMP plays a role in the toxicity profile is not equal to that of dapsone [29] . This compound has not been evaluated in clinical trials for PCP.
known. Such a role might come from a direct adverse effect of TMP or might be due to an associated increase in the plasma concentration of dapsone, as shown in one of the studies by Clinical Trials: Treatment Lee et al. [14] and discussed herein in the section on metabolism and pharmacokinetics. In 1991 Safrin et al. [33] concluded that a high-dose, singleagent regimen of dapsone was not suitable for further study or (100 mg/d) and TMP (20 mg/[kgrd]) were given orally. Fifteen patients were studied. The pretreatment arterial oxygen tension as therapy for PCP and that this therapy should not be clinically employed. Their study was a prospective one of seven patients ranged from 48 to 82 torr (median, 68.1 torr) in 14 of the patients, and one patient's value was 104 torr. The conditions with mild PCP. Patients were treated with 200 mg of dapsone daily. None of the seven patients successfully completed a full of all 15 patients improved clinically and radiographically within 3 -10 days after the start of dapsone/TMP therapy. Concourse of treatment with dapsone; two patients died, and four experienced major side effects. There was no explanation for tinued improvement was noted at the end of 3 weeks of treatment.
these poor responses in comparison with those in other studies.
In 1996 a randomized, double-blind study (ACTG [AIDS Fourteen of the patients had adverse reactions (nausea and vomiting in 6, maculopapular rash in 8, decrease in hematocrit Clinical Trials Group] 108) was reported by Safrin et al. [34] that involved 181 AIDS patients with cytologically documented (ú5%) in 7, neutropenia in 1, and thrombocytopenia in 1). Two patients had to be withdrawn from the therapy because PCP, who were randomized to receive treatment with one of three drug regimens: dapsone plus TMP, TMP-SMZ, or clindaof rash. Six patients had an increase in hepatic transaminase levels. The observed 100% initial response rate (95% CI, 78% -mycin plus primaquine. Dapsone was used at a dosage of 100 mg/d. Treatment was given over a period of 21 days. 100%) and 87% overall efficacy (95% CI, 58% -98%) were equal to or better than the values noted in a comparable study
The results showed no significant differences among the groups with respect to therapeutic failure (P ú .2), survival with TMP-SMZ and pentamidine.
Because of the success of the initial study with use of both during therapy or for 2 months thereafter (P ú .2), and treatmentlimiting toxicity (P Å .2) (figures 1 and 2). However, elevation dapsone and TMP, the second planned study was undertaken to evaluate dapsone alone [31] . As shown in animal studies, of serum aminotransferase levels to more than five times the baseline levels was more frequent in the TMP-SMZ group the single-drug therapy was effective but not as effective as the combination. The 18 patients with AIDS and PCP admitted (P Å .003), and one or more serious hematologic toxic effects (neutropenia, anemia, thrombocytopenia, or methemoglobinto San Francisco General Hospital between April 1985 and July 1985 were given dapsone (100 mg/d) orally for 21 days. emia) occurred more frequently in the clindamycin/primaquine group (P Å .01). Of the 8 deaths (4.4%) during the 81-day period The conditions of 7 (39%) of the 18 patients worsened during dapsone therapy, and these cases were considered treatment of observation, 4 were in the TMP-SMZ group, 2 in the dapsone/ TMP group, and 2 in the clindamycin/primaquine group. While failures; the conditions of the remaining 11 (61%) improved within 3 -10 days after administration of dapsone was started.
this is the largest trial evaluating the therapeutic efficacy of dapsone, the limited sample size prevented unequivocal demonstraAdverse reactions were noted in 6 of the 11 patients whose dapsone therapy was maintained (rash in 6 patients and abnortion of the equality of these three regimens. Several single case reports describe the successful treatment mal liver enzyme levels in 2). However, no toxic effect necessitating termination of treatment occurred.
of PCP with dapsone, with and without TMP [35 -38] . At once a day orally; (2) dapsone, 50 mg daily, plus pyrimethamine, 50 mg once a week, and leucovorin, 25 mg once a week orally; or (3) dapsone, 200 mg, plus pyrimethamine, 75 mg, and leucovorin, 25 mg once a week orally. The dapsone dose recommended as PCP prophylaxis for children is 2.0 mg/(kgrd), not to exceed 100 mg daily.
In the early years of the AIDS epidemic, before PCP prophylaxis became established as standard practice, PCP occurred in 80% of persons with AIDS and was the AIDS-defining illness in ú60% of patients [83] . Effective chemoprophylaxis and more effective primary treatment for HIV infection have brought about an impressive reduction in PCP among patients with HIV infection.
Unfortunately, despite these effective prophylactic regimens, PCP continues to be a significant opportunistic infection in AIDS. A longitudinal cohort study in the Multicenter AIDS Cohort Project, reported in 1995 [84] , identified factors associated with failure of PCP prophylaxis in patients prescribed TMP-SMZ, dapsone, or aerosolized pentamidine. The main predictor of failure of prophylaxis was profound lymphopenia affecting CD4
/ lymphocyte counts. Of the 476 patients receiv- tamidine (14.5% of patients per year) and dapsone (13.5% per [34] with permission.
year) than among those given TMP-SMZ (9.8% per year) as the initial regimen. Although more than 40 studies involved the use of dapsone as prophylaxis for PCP, these investigations have varied greatly present one may conclude that dapsone, with or without TMP, is effective in the treatment of PCP, but the drug combination is most effective. TMP/dapsone is probably similar in efficacy to TMP-SMZ for mild and moderately severe PCP. Dapsone alone is not indicated for treatment. Some but not all patients who have experienced adverse reactions to TMP-SMZ will be able to tolerate TMP/dapsone.
Clinical Trials: Prophylaxis
The greatest use of dapsone in the management of PCP has been as prophylaxis for patients at high risk for this infection. The efficacy demonstrated in animal studies has also been demonstrated in at least 41 clinical trials involving HIV-infected individuals (table 1) . Two major advantages of dapsone are its long halflife, allowing infrequent dosing, and low cost. Some evidence suggests dapsone in combination with pyrimethamine may prevent mycobacterial infections [81] and toxoplasmosis [62] .
Efficacy with regard to the successful prevention of PCP has been demonstrated in clinical trials of four drugs: TMP-SMZ, dapsone, aerosolized pentamidine, and atovaquone. TMP-SMZ is considered the first choice for those who can tolerate the drug. Dapsone was recommended in the ''1997 USPHS/IDSA in experimental design, dapsone dosages, and intervals of adoccurred in 55% of patients given 50 mg of dapsone daily, whereas in another study [39] only 10% of patients had adverse ministration. Dosages ranged from 50 to 300 mg/d, with and without pyrimethamine, and at intervals from daily to weekly.
reactions when given double this dose (100 mg). However, general comparison of adverse reactions to dapsone and to Dapsone prophylaxis has been compared to that with TMP-SMZ, aerosolized pentamidine, fansidar, clindamycin/primaother drugs can be made within each study. From review of all the studies (table 1) , one can generally conclude that adverse quine, and atovaquone in retrospective and prospective studies and in randomized and nonrandomized studies. Unfortunately, reactions occur more frequently with dapsone than with aerosolized pentamidine and that no striking differences are seen no study has been blinded, and most of the studies have not had a sufficient number of subjects or time of observation to between dapsone and TMP-SMZ. Some perspective on the relative efficacy of dapsone with allow statistically sound conclusions to be drawn. In addition, studies of TMP plus dapsone, shown to be synergistic in anirespect to TMP-SMZ and aerosolized pentamidine can be gleaned from the studies reported. Among the 16 studies in mals [21] , have not been done in humans. Instead, pyrimethamine has been used in combination with dapsone, intended which dapsone, with and without pyrimethamine, was compared with TMP-SMZ, the rate of break-through PCP was in most studies to extend the spectrum of coverage to T. gondii. However, there are no studies and little rationale to suggest greater with dapsone in 11 of the studies [53, 55, 58, 60, 66, 68, 70, 71, 76 -78] , and in 5 [39, 56, 73 -75 ] the break-through that TMP would be less effective than pyrimethamine in combination with dapsone against T. gondii.
rates were similar. In 15 studies dapsone was compared with aerosolized penOnly three studies have compared dapsone prophylaxis with no prophylaxis. None of these were randomized studies. However, tamidine [45, 52, 53, 57, 60 -62, 65, 68 -70, 72 -74, 77] , and no statistically significant difference in rates of break-through these comparisons are convincing evidence of the anti-P. carinii activity of dapsone. Metroka et al. [39] found that 100% of 23 PCP were discernible, although in one study [70] PCP occurred in 14.3% of those receiving dapsone and pyrimethamine and high-risk AIDS patients not given prophylaxis developed PCP over a period of 9.6 months, whereas only 2 (1.0%) of 173 patients 5.8% of those receiving pentamidine. Salmon-Céron et al. [69] found lower survival among AIDS patients taking dapsone than given 100 mg of dapsone daily had PCP over the same period of time. Lucas et al. [40] noted PCP in 16 (35%) of 46 patients among those receiving aerosolized pentamidine for prophylaxis. This European study randomized 196 AIDS patients to not receiving prophylaxis and in 1 (6.3%) of 16 patients taking 100 mg of dapsone once a week. Penco [50] reported the occurreceive either aerosolized pentamidine (300 mg monthly) or dapsone (50 mg daily). rence of PCP in 8 (80%) of 10 patients not receiving prophylaxis during a 6-month period, while only 1 (10%) of 10 AIDS patients After a follow-up (mean { SD) of 13 { 6.4 months, the study was prematurely terminated because of excessive morgiven 50 mg of dapsone twice weekly had PCP during a 12-month period of observation (table 1) . tality in the dapsone group; 21% of the 103 patients in the pentamidine group vs. 42% of the 93 receiving dapsone had There are no conclusive data to support or to discount the use of pyrimethamine with dapsone as prophylaxis for PCP died. The mean CD4 cell count during the study was lower in the dapsone group. The dapsone preparation used in this because adequate comparative studies have not been done. In the small randomized study of 55 patients by Lavelle et al.
study contained 200 mg of iron protoxalate per tablet. Weinberg [85] suggests the increased iron burden from this formu- [47] , dapsone (200 mg/w) was compared with the same dose plus 25 mg of pyrimethamine per week. Break-through PCP lation might have contributed to the lower survival rate. He has shown that iron chelators inhibit the growth of P. carinii occurred in 4.3% and 4.5% of the groups, respectively. Adverse reactions occurred in 13% and 18% of the respective groups.
in cell culture and are effective in the treatment of PCP in animals [86, 87] . When the confounding variables in the clinical trials are considered, no specific dose or schedule of administration Bucker et al. [88] utilized a meta-analysis to examine the efficacy of dapsone (and dapsone plus pyrimethamine), TMPcan be selected as more effective than others (see table 1 ). In studies with 100-mg daily doses of dapsone alone, rates SMZ, and aerosolized pentamidine in patients with HIV infection. The analysis included 4,832 patients in 22 trials. For the of break-through PCP of 1% [39] , 0 [42] , 2% [56] , 12% [63] , 17% [74] , 18% [79] , and 21% [68] were encountered.
1,548 patients given dapsone, with or without pyrimethamine, and the 1,800 patients receiving aerosolized pentamidine, the When 100 mg of dapsone was given once a week, breakthrough rates were 2% [44] , 4% [43] , and 6% [67] . When risk ratio for PCP was 0.90 (95% CI, 0.71 -1.15). For the 1,484 patients given TMP-SMZ vs. the dapsone group, the risk ratio dapsone was used alone at a dosage of 50 mg/d, breakthrough PCP occurred in 0 [51] , 5% [42] , 5.7% [69] , 6.5% of PCP was 0.49 (95% CI, 0.26 -0.92). For TMP-SMZ vs. aerosolized pentamidine, the risk ratio of PCP was 0.59 (95% [53] , and 13% of patients [77] .
Accurate comparison of adverse reaction rates among the CI, 0.45 -0.76). The report by El Sadr et al. [79] shows atovaquone to be as clinical trials reported is not possible because of the variations in the definitions for adverse events, periods of observation, and effective as dapsone in PCP prophylaxis. Future studies will place this drug in perspective for PCP prophylaxis. other factors. For example, in one study [53] adverse reactions / 9c51$$jy36 06-16-98 00:27:17 cida UC: CID It seems reasonable to conclude that dapsone is not superior Balestrini et al. [92] studied the adverse events in 261 HIVinfected patients taking dapsone as prophylaxis for PCP. Sevto any drug as prophylaxis for PCP, is somewhat less effective than TMP-SMZ, and is equal to aerosolized pentamidine in effienty-one patients (27%) stopped taking the drug; 23 had rash; 10 had hematologic toxicity; 10 had malaise or nausea; and 10 cacy. Several factors must be considered in choosing between dapsone and aerosolized pentamidine for patients who cannot died of causes not related to dapsone. Because of the doubleblind, randomized design of the study by Medina et al. [93] , take TMP-SMZ. For example, infants, children, and some adults may not be able to take aerosolized pentamidine, and aerosol a valid comparison of adverse effects from dapsone/TMP and TMP-SMZ can be made. Patients with known allergy to any administration may be hazardous when the patient has a contagious respiratory tract infection. Cost is also a major factor.
of the drugs were excluded from the study. The drugs were given for the treatment of PCP. Dosages used were 20 mg of TMP plus 100 mg of SMZ/(kgrd) and 20 mg of TMP/(kgrd) Cost of Prophylaxis plus 100 mg (total dose) of dapsone daily. Major toxic effects that required a change to another drug A dapsone regimen is the most economical currently availoccurred in 9 (30%) of 30 patients receiving dapsone/TMP and able for prophylaxis for both individual and population use.
in 17 (57%) of 30 patients receiving TMP-SMZ (P õ .025). The annual cost (in $U.S.) of PCP prophylaxis for an adult is Abnormally high liver transaminase levels occurred in 1 and $8,190 for atovaquone, $1,200 for aerosolized pentamidine, 6, neutropenia (õ750 neutrophils/mm 3 ) in 1 and 5, thrombocyand $30 for TMP-SMZ (3 days a week), in comparison with topenia in 1 and 1, severe rash in 3 and 3, nausea and vomiting $70 for daily dapsone and $10 for weekly dapsone [89] . Howin 2 and 2, a decline in hematocrit by §25% in 0 and 0, and ever, efficacy and safety must be factored into the cost equation.
methemoglobinemia (ú20%) in 1 and 0 of the patients receivUsing a decision-analytic model, Freedberg et al. [90] assessed ing dapsone/TMP and TMP-SMZ, respectively. Therapeutic the effectiveness and costs of dapsone, TMP-SMZ, and aerosolefficacy was similar in the two groups. ized pentamidine as initial prophylaxis for PCP in HIV-infected Beumont et al. [94] assessed the safety of dapsone prophylaxis individuals with CD4
/ lymphocyte counts of õ200/mm 3 . Each in patients who had previously been found intolerant of TMPstrategy increased life expectancy by about 18%, compared SMZ. Of 75 patients subsequently given dapsone, the overall with that with no prophylaxis. Annual per-person costs were incidence of adverse events was 39%. Rash (16%) and anemia $400 for dapsone, $700 for TMP-SMZ, and $1,680 for aerosol-(23%) were the most common events. However, when each case ized pentamidine. They estimated that for 100,000 people rewas evaluated critically, only three cases of anemia (4%) and two ceiving prophylaxis with TMP-SMZ or dapsone (and switching cases of rash (3%) were considered ''likely related'' to dapsone. to aerosolized pentamidine if oral therapy is not tolerated), the Only five (6.7%) of the 75 patients had the same adverse event savings in medical costs is between $8 million and $124 million as previously experienced with TMP-SMZ. per year.
A retrospective review of 89 patients receiving dapsone because of prior adverse reactions to TMP-SMZ showed 56% experienced single or multiple adverse reactions (maculopapuAdverse Effects lar rash in 27 patients, CNS symptoms in 15, gastrointestinal symptoms in 8, and anemia in 12) [95] . Adverse effects of dapsone include a dose-related hemolysis seen in most patients receiving high dosages of §200 mg/d.
Few HIV-infected patients who receive PCP prophylaxis take only the drug or drugs prescribed for this purpose. The Methemoglobinemia may occur at symptomatic and asymptomatic levels. Peripheral motor weakness may also occur with concomitant use of several drugs adds to the complexity in sorting out the adverse effects of one specifically. Moore et al. high doses. Adverse reactions unrelated to dosage include agranulocytosis, aplastic anemia, a variety of cutaneous reac- [96] attempted to quantify the incidence of these effects in clinical practice. They calculated the overall adverse event rates tions, and a ''sulfone syndrome'' (fever, exfoliative dermatitis, jaundice, lymphadenopathy, anemia, and methemoglobinemia) from the use of dapsone, TMP-SMZ, zidovudine, didanosine, and zalcitabine in an observational cohort of 1,450 HIV-inbelieved to be a hypersensitivity reaction occurring after 6 -8 weeks of treatment.
fected patients with CD4 / lymphocyte counts of £500/mm 3 . The rates are given in table 2. The adverse events from dapsone Although adverse reactions are fairly common with dapsone, fatalities are rare. Useful information on toxicity has come were not related to CD4 / lymphocyte count, race, gender, age, or injection drug use. from studies of a patient without AIDS who consumed a single 2,500-mg dose of dapsone, 25 times the usual daily dose [91] .
A desensitization scheme has been evaluated by Metroka et al. [97] for patients with hypersensitivity-like reactions to The next day he was noted to have blue skin. Twenty hours post-dose the methemoglobin concentration was 2.5 g/dL (25% dapsone. Fourteen patients who had fever (ú39ЊC) and diffuse erythematous maculopapular rash that appeared 8 -14 days of total hemoglobin). The plasma dapsone level was 18.8 mg/L. The patient had an uneventful recovery without specific after initiation of dapsone therapy were desensitized over a period of 42 days. Daily doses of dapsone escalated from therapy.
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06-16-98 00:27:17 cida UC: CID inhibited MADDS formation [106] . No inhibition was observed with atovaquone, sulfadiazine, clarithromycin, TMP, ketoconazole, and fluconazole. This experiment suggests that NAT-2 is the predominant liver NAT isoform acetylating dapsone in vivo 0.01 mg initially to 90 mg by day 37. Thirteen of the 14 patients were successfully desensitized and once again were given dapand that coadministration with other anti -opportunistic infection drugs should not inhibit this acetylation pathway. sone prophylaxis for up to 7 months at the full dosage of 100 mg/d. The 14th patient developed a recurrent diffuse rash on Studies to elucidate the mechanism of increases in serum creatinine level, sometimes associated with the administration day 42.
Holtzer et al. [98] studied 60 HIV-infected patients who had of pyrimethamine plus dapsone, show this abnormality is due to the renal tubular secretion of creatinine by pyrimethamine. hypersensitivity reactions (anaphylaxis, rash, hives, pruritis, or drug fever) to TMP-SMZ and were subsequently given dapsone
The inhibition is reversible and does not affect the glomerular filtration rate [107] . as prophylaxis for PCP. Thirteen (22%) of the 60 patients also had hypersensitivity reactions to dapsone. Four (30.8%) of the Wu and DuBois [108] demonstrated that dapsone inhibits oxidation of pyruvate in rat and mouse tissues by interfering 13 patients were able to continue receiving dapsone despite the adverse reaction. Thus, up to 85% of patients with adverse with the pyruvate oxidase system. Because thymine pyrophosphate is needed for normal function of pyruvic oxidase and reactions to TMP-SMZ might be expected to tolerate prophylaxis with dapsone.
because thymine deficiency is associated with symptoms of dapsone poisoning, an animal study was done to supplement The classic sulfone syndrome (fever, hemolytic anemia, and fulminant hepatitis) was reported in the first fatal case of dapdapsone administration with thymine hydrochloride. The results showed that the LD 50 for control rats given dapsone alone sone toxicity [99] . Mole-Boetani et al. [100] reported the first case of the sulfone syndrome involving a patient with AIDS was 233 mg/kg, whereas if dapsone were given with thymine hydrochloride the LD 50 was 425 mg/kg. No clinical studies and reviewed the 22 cases of sulfone syndrome in non-AIDS patients reported in the literature. The AIDS patient's syndrome have evaluated the use of thymine in dapsone toxicity. One case of dapsone toxicity with megaloblastic pancytoperesolved, and he was discharged after 10 days in the hospital.
Methemoglobinemia in HIV-infected patients receiving dapnia associated with vitamin B 12 deficiency has been reported [109] , suggesting that supplemental folic acid might be indisone has been reported infrequently, although this is wellknown as a toxic effect from its early use in non-AIDS patients. cated when this is likely to occur. Sin et al.
[101] described five AIDS patients who had symptomatic methemoglobinemia while taking either primaquine or dapConclusion sone alone or in combination. Two cases resulted from intentional overdoses of dapsone, and three cases developed within Dapsone is effective in the prevention of PCP and in combination with TMP is effective in the treatment of this pneumonia few days of starting primaquine while the patients were receiving dapsone. Four cases required iv methylene blue, suptis. It is not the drug of first choice for either prophylaxis or treatment for patients who can take TMP-SMZ. The data curplemental oxygen, and RBC transfusion.
It is well-known that the risk of methemoglobinemia is inrently available are adequate to consider it as a drug of second choice for patients who have experienced adverse effects from creased greatly if two or more drugs, such as primaquine and dapsone, known to cause this condition, are combined [102] .
TMP-SMZ. Most but not all patients with such effects will be able to take dapsone safely. The most serious adverse effects Blood gas studies and pulse oximetry may not be affected by methemoglobinemia in the usual concentrations encountered from dapsone are dose-related hemolytic anemia, peripheral motor weakness, and methemoglobinemia as well as dose-unrewith dapsone toxicity. However, with a normal cardiorespiratory system and 100% methemoglobinemia, an oxygen saturalated granulocytopenia, aplastic anemia, and cutaneous reactions such as the sulfone syndrome. tion of 85% may be expected with use of conventional pulse oximetry [96] . Co-oximetry, which measures all major hemoAlthough the number of studies to clearly define the optimal dose and schedule for administration is limited, the following globin species, is accurate in this setting.
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